FindTrial
Sign In

A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory anaplastic large cell lymphoma or classical Hodgkin lymphoma

A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory anaplastic large cell lymphoma or classical Hodgkin lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003789
Enrollment
150
Registered
2019-04-16
Start date
2018-12-06
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Any patient planning to administer BrentuximabVedotin to treat the target disease. 2) Any patient administering BrentuximabVedotin to treat the target disease. 3) Any patient tracing BrentuximabVedotin after treating the target disease. 4) Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin

Exclusion criteria

Exclusion criteria: If conditions for target diseases are not met. If conditions for target patients are not met. If patients do not give written consent to participate in study.

Design outcomes

Primary

MeasureTime frame
Overall response rate—

Secondary

MeasureTime frame
Response retention period;Survival with no therapy;Overall survival period;Length of time until next treatment—

Countries

Korea, Republic of

Contacts

Public ContactSeokjin Kim

Samsung Medical Center

info@cisl.co.kr+82-2-3410-1766

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026